Nonhematologic toxicity CTC 2-4 grade after intermediate-dose melphalan (IDM) cycles I and II (%) and myeloablative treatment
| . | Treatment period . | Myeloablative therapy, n = 104 . | |
|---|---|---|---|
| IDM cycle 1, n = 254 . | IDM cycle 2, n = 206 . | ||
| Liver | 2 | 1 | 13 |
| Mucositis | 9 | 6 | 45 |
| Nausea | 11 | 11 | 22 |
| Vomiting | 7 | 8 | 18 |
| Diarrhea | 4 | 3 | 20 |
| Renal | 2 | 1 | 3 |
| Fever | 4 | 3 | 18 |
| Allergy | 2 | 2 | 3 |
| Cutaneous | 6 | 3 | 12 |
| Cardiac | 2 | 1 | 6 |
| Neurologic | 2 | 2 | 5 |
| Other | 11 | 11 | 34 |
| Maximum CTC 2 | 28 | 26 | 31 |
| Maximum CTC 3 | 7 | 4 | 28 |
| Maximum CTC 4 | 2 | 1 | 17 |
| . | Treatment period . | Myeloablative therapy, n = 104 . | |
|---|---|---|---|
| IDM cycle 1, n = 254 . | IDM cycle 2, n = 206 . | ||
| Liver | 2 | 1 | 13 |
| Mucositis | 9 | 6 | 45 |
| Nausea | 11 | 11 | 22 |
| Vomiting | 7 | 8 | 18 |
| Diarrhea | 4 | 3 | 20 |
| Renal | 2 | 1 | 3 |
| Fever | 4 | 3 | 18 |
| Allergy | 2 | 2 | 3 |
| Cutaneous | 6 | 3 | 12 |
| Cardiac | 2 | 1 | 6 |
| Neurologic | 2 | 2 | 5 |
| Other | 11 | 11 | 34 |
| Maximum CTC 2 | 28 | 26 | 31 |
| Maximum CTC 3 | 7 | 4 | 28 |
| Maximum CTC 4 | 2 | 1 | 17 |